COEPライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 05:00):

Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer...

Stats
本日の出来高	52 424.00
平均出来高	258 315
時価総額	11.42M
EPS	$0 ( 2024-03-28 )
次の収益日	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.550
ATR14	$0.00600 (1.79%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-10	Cogley Brian	Buy	5 000	Common Stock
2024-01-10	Cogley Brian	Sell	0	Common Stock
2024-01-12	Desilva Tara	Buy	1 800	Common Stock
2024-01-12	Desilva Tara	Buy	466	Common Stock
2024-01-05	Yerace Daniel Alexander	Buy	10 850	Common Stock

INSIDER POWER
67.71
Last 46 transactions
Buy: 10 280 996 \| Sell: 12 141 291

ボリューム相関

長: 0.05 (neutral)

短: -0.03 (neutral)

Signal:(57.83) Neutral

Coeptis Therapeutics, 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Coeptis Therapeutics, 相関 - 通貨/商品

0.00
( neutral )

0.03
( neutral )

0.00
( neutral )

0.09
( neutral )

Coeptis Therapeutics, 財務諸表

Annual	2023
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-0.830

FY	2023
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-0.830

FY	2022
収益:	$0
総利益:	$-1.00M (0.00 %)
EPS:	$-2.87

FY	2021
収益:	$75 000.00
総利益:	$75 000.00 (100.00 %)
EPS:	$-0.689

Financial Reports:

No articles found.

Coeptis Therapeutics,

Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.